| Taselisib studied in …STUDIED_INderived11 of 11show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 11 trials list this drug (2 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02390427Phase 1 · completed Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer · 11 trials list this drug (2 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439175Phase 2 · active not recruiting Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) · 11 trials list this drug (2 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01296555Phase 1 · terminated A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer · 11 trials list this drug (2 active) | — | — | Malignant Solid Neoplasm,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02154490completed Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer · 11 trials list this drug (2 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02285179Phase 1/Phase 2 · completed Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen · 11 trials list this drug (2 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02457910Phase 1/Phase 2 · terminated Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer · 11 trials list this drug (2 active) | — | — | Malignant Breast Neoplasm,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02340221Phase 3 · terminated A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy · 11 trials list this drug (2 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02785913Phase 2 · completed Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches · 11 trials list this drug (2 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02273973Phase 2 · completed A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) · 11 trials list this drug (2 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01862081Phase 1 · completed A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer · 11 trials list this drug (2 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |